Day One Biopharmaceuticals, Inc. (DAWN) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 6 Buy, 6 Hold.
The consensus price target is $23.75 (low: $21.50, high: $26.00), representing an upside of 10.7% from the current price $21.46.
Analysts estimate Earnings Per Share (EPS) of $-0.73 and revenue of $0.12B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.02 vs est $-0.73 (missed -40.2%). 2025: actual $-1.04 vs est $-0.99 (missed -5.2%). Analyst accuracy: 83%.
DAWN Stock — 12-Month Price Forecast
$23.75
▲ +10.67% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Day One Biopharmaceuticals, Inc., the average price target is $23.75, with a high forecast of $26.00, and a low forecast of $21.50.
The average price target represents a +10.67% change from the last price of $21.46.
Highest Price Target
$26.00
Average Price Target
$23.75
Lowest Price Target
$21.50
DAWN Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Day One Biopharmaceuticals, Inc. in the past 3 months
EPS Estimates — DAWN
83%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.02
vs Est –$0.73
▼ 28.7% off
2025
Actual –$1.04
vs Est –$0.99
▼ 4.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — DAWN
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.131B
vs Est $0.123B
▲ 6.6% off
2025
Actual $0.158B
vs Est $0.154B
▲ 2.4% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
